

RESEARCH MONOGRAPH . COMPOUND PROFILE

Alpha-GPC

A high-bioavailability choline donor derived from phosphatidylcholine hydrolysis, developed in Italy as a prescription cholinergic agent for cognitive impairment and cerebrovascular disease, distinguished from other choline sources by efficient blood-brain barrier penetration and dual contribution of choline for acetylcholine synthesis and glycerophosphate for membrane phospholipid remodeling.

DOCUMENT	KDC-MN-1443
ISSUED	2026-05-11
REVISION	1.0
AUTHOR	Kodiac biolabs Research
COMPOUND CLASS	Phospholipid-derived cholinergic precursor and acetylcholine biosynthetic substrate

ABSTRACT

Alpha-GPC (L-alpha-glycerylphosphorylcholine; choline alfoscerate; sn-glycero-3-phosphocholine; CAS 28319-77-9; molecular formula C₈H₂₀NO₆P; molecular weight 257.22 g/mol) is an endogenous phospholipid intermediate in the deacylation pathway of membrane phosphatidylcholine and an exogenous cholinergic precursor that delivers bioavailable choline across the blood-brain barrier more efficiently than choline salts, choline bitartrate, or lecithin. The compound contains approximately 40 percent choline by mass, is freely water-soluble, highly hygroscopic, and is metabolized by phosphodiesterases in the intestinal mucosa and in central and peripheral tissues to yield free choline and glycerol-3-phosphate. The released choline serves as the immediate biosynthetic substrate for choline acetyltransferase-catalyzed acetylcholine synthesis in cholinergic neurons, while the glycerophosphate moiety enters the Kennedy pathway for phosphatidylcholine resynthesis, providing simultaneous support for neurotransmitter production and neuronal membrane integrity.

Alpha-GPC was first synthesized by Baer and Kates in 1948 and entered pharmaceutical development in Italy in the 1980s under the trade names Gliatilin and Delecit. It is registered as a prescription medicine in Italy, Russia, and several Eastern European and Asian jurisdictions for the treatment of cognitive impairment associated with Alzheimer disease, cerebrovascular disease, and post-stroke cognitive decline. In the United States it is classified as a dietary supplement and is not regulated as a drug. The compound has accumulated a substantial clinical evidence

base across multiple indications: a 2044-patient Italian multicenter trial in acute cerebrovascular disease (Barbagallo Sangiorgi et al. 1994); the De Jesus Moreno (2003) 261-patient multicenter randomized double-blind placebo-controlled trial demonstrating significant improvement on the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog), Mini-Mental State Examination (MMSE), and Global Deterioration Scale (GDS) at 1200 mg/day for 180 days in mild-to-moderate Alzheimer dementia; multiple open-label and controlled studies of combination therapy with acetylcholinesterase inhibitors; and recent systematic reviews and meta-analyses (Sagaro et al. 2023) confirming efficacy in adult-onset cognitive dysfunction with pooled effect sizes favoring alpha-GPC over placebo and over citicoline in head-to-head comparisons. Additional research applications include augmentation of growth hormone secretion during resistance exercise (Ziegenfuss et al. 2008), enhancement of peak force production in trained athletes, and investigation of motivational and attentional endpoints in healthy volunteers.

Pharmacokinetics are characterized by rapid oral absorption with peak plasma choline elevation at approximately 1 to 2 hours, a choline elevation half-life of 4 to 8 hours, oral bioavailability exceeding 40 percent for choline delivery, and metabolism through phosphodiesterase-mediated hydrolysis rather than cytochrome P450-dependent pathways. The compound distributes widely, with particular concentration in brain, liver, and kidney. Excretion is predominantly renal as polar choline metabolites and expired carbon dioxide from betaine oxidation.

The safety profile at registered doses (400 to 1200 mg/day) is favorable; the most commonly reported adverse events are mild gastrointestinal disturbance (nausea, heartburn, diarrhea),

headache, and insomnia, occurring at rates modestly above placebo. A 2021 Korean retrospective cohort study (Lee et al. 2021) raised a signal for increased stroke risk with long-term alpha-GPC use, a finding that requires replication and mechanistic investigation. The proposed mechanism involves conversion of choline to trimethylamine by gut microbiota, hepatic oxidation to trimethylamine N-oxide (TMAO), and TMAO-mediated promotion of atherosclerosis and thrombosis. This signal has not been confirmed in prospective controlled trials and does not apply to short-term or moderate-dose use.

This monograph documents the chemistry, synthesis, and preparation of alpha-GPC; the cholinergic precursor mechanism and downstream pharmacology; comprehensive pharmacokinetics; the clinical evidence base across cognitive, cerebrovascular, sport-performance, and adjunctive indications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; the adverse-event and safety signal; and a structured comparative assessment of five alternative choline donors and cholinergic precursors (citicoline, choline bitartrate, phosphatidylcholine, DMAE, and centrophenoxine) against alpha-GPC on five standards: bioavailability, effect size, clinical validation, side-effect profile, and overall utility.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

International Nonproprietary Name: Choline alfoscerate (INN).

Common name: Alpha-GPC (alpha-glycerylphosphorylcholine).

Marketed names: Gliatilin (Italfarmaco; Italy, Russia, several Commonwealth of Independent States countries), Delecit (generic markets), Cereton (Russia), Cholitilin (Russia, Eastern Europe).

Chemical Abstracts Service registry number: 28319-77-9.

International Union of Pure and Applied Chemistry name: (2R)-2,3-dihydroxypropyl 2-(trimethylammonio)ethyl phosphate. The compound is the sn-glycero-3-phosphocholine stereoisomer, with the (R)-configuration at carbon 2 of the glycerol backbone corresponding to the naturally occurring L-form derived from membrane phosphatidylcholine.

PubChem CID: 71920.

DrugBank ID: DB12093.

Other synonyms: L-alpha-glycerylphosphorylcholine, sn-glycero-3-phosphocholine, GPC, glycerophosphocholine, choline glycerophosphate.

1.2 Structural class and chemistry

Alpha-GPC is a phospholipid derivative belonging to the glycerophosphocholine class. It is the deacylated backbone of phosphatidylcholine, retaining the glycerol-phosphate-choline head group without the two fatty acyl chains. The structural class places it within the lysophospholipid and phosphodiester families, intermediate between the intact membrane phospholipid (phosphatidylcholine) and the free polar head group components (choline and glycerol-3-phosphate) [1].

Molecular formula: C₈H₂₀NO₆P.

Molecular weight: 257.22 g/mol.

Choline content by mass: Approximately 40 percent (choline molecular weight 104.17 / alpha-GPC molecular weight 257.22 = 0.405).

Physical properties: White to off-white hygroscopic powder or viscous liquid (depending on water content). Freely soluble in water (approximately 1000 g/L at 25 degrees Celsius), soluble in methanol and dimethyl sulfoxide, insoluble in chloroform, diethyl ether, and nonpolar organic solvents. Melting point approximately 143 degrees Celsius. Density approximately 0.791 g/mL at 25 degrees Celsius. The compound is highly hygroscopic and readily absorbs atmospheric moisture; commercial preparations are typically supplied as a 50 percent alpha-GPC powder (alpha-GPC adsorbed onto silica or other carriers to prevent deliquescence) or as a 99 percent anhydrous powder requiring desiccated storage [2].

Stereochemistry: Alpha-GPC contains one stereocenter at carbon 2 of the glycerol backbone. The naturally occurring and commercially supplied form is the (2R) enantiomer, corresponding to the sn-glycero-3-phosphocholine configuration derived from L-phosphatidylcholine. The stereochemistry is preserved in enzymatic preparation from natural phosphatidylcholine; chemical synthesis may produce racemic material unless stereoselective methods are employed.

1.3 Synthesis and preparation

Alpha-GPC is produced by three principal methods: enzymatic hydrolysis of natural phosphatidylcholine, chemical deacylation of phosphatidylcholine, and total chemical synthesis [3, 4].

Enzymatic preparation (industrial standard): The dominant commercial production method involves enzymatic hydrolysis of soy or sunflower phosphatidylcholine using phospholipase A1 or phospholipase A2, which cleave the sn-1 and sn-2 fatty acyl ester bonds, respectively, to yield first lysophosphatidylcholine and then alpha-GPC. Phospholipase A1 from *Thermomyces lanuginosus* (Lecitase Ultra) is the most commonly employed enzyme. Optimized conditions (55 degrees Celsius, water-in-oil emulsion, 3 hours reaction time, 5 weight percent enzyme loading) achieve greater than 95 percent conversion of phosphatidylcholine to alpha-GPC [3]. *Candida antarctica* lipase B has also been used with comparable yields at 55 degrees Celsius and 6 to 8 hours reaction time [4]. The product is purified by chromatographic separation (ion exchange or silica gel), decolorization, and lyophilization or spray drying. The enzymatic method preserves the natural (2R) stereochemistry and avoids harsh chemical conditions.

Chemical deacylation: Alkaline hydrolysis (sodium hydroxide or potassium hydroxide in aqueous methanol) of phosphatidylcholine cleaves the acyl ester bonds to yield alpha-GPC and fatty acid salts. This method is simpler but produces racemization risk at elevated temperatures and requires more extensive purification to remove soap byproducts and residual base.

Total synthesis: The Baer and Kates (1948) synthesis from glycerol, phosphorus oxychloride, and trimethylamine established the compound structurally but is not used commercially [5]. Modern total syntheses employ glycidol ring-opening or phosphoramidite chemistry and are used principally for isotope-labeled preparations ([¹⁴C]-alpha-GPC, [³H]-alpha-GPC) for pharmacokinetic tracer studies.

Fermentation: Microbial fermentation of wheat or other carbohydrate substrates has been demonstrated to produce alpha-GPC, though this method is not yet widely commercialized [6].

2. Abstract

Alpha-GPC (L-alpha-glycerylphosphorylcholine; choline alfoscerate) is a water-soluble phospholipid metabolite that functions as a high-efficiency choline donor for the central and peripheral nervous system. The compound is an endogenous intermediate in the deacylation pathway of membrane phosphatidylcholine, produced constitutively in all nucleated cells and present at measurable concentrations in brain, liver, kidney, and plasma [7]. As an exogenous agent, alpha-GPC is distinguished from other choline sources (choline bitartrate, choline chloride, phosphatidylcholine, citicoline) by three pharmacological features: superior bioavailability for raising plasma and brain choline concentrations after oral administration; dual metabolic contribution of both choline (for acetylcholine synthesis) and glycerophosphate (for phospholipid membrane remodeling); and efficient transport across the blood-brain barrier through specific choline transport mechanisms [8, 9].

The cholinergic precursor mechanism is the foundation of the clinical evidence base. Alpha-GPC at oral doses of 400 to 1200 mg/day has been evaluated in multiple randomized controlled trials across cognitive impairment in Alzheimer disease, vascular dementia, and post-stroke cognitive decline. The De Jesus Moreno (2003) multicenter double-blind placebo-controlled trial in 261 patients with mild-to-moderate Alzheimer dementia demonstrated a 3.20-point improvement on the ADAS-Cog at day 180 in the alpha-GPC group versus a 2.90-point worsening in the placebo group ($p < 0.001$), with consistent improvements on MMSE, GDS, and Clinical Global Impression scales [10]. The Barbagallo Sangiorgi et al. (1994) multicenter trial in 2044 patients with recent stroke or transient ischemic attack demonstrated cognitive and functional recovery with alpha-GPC at 1000 mg/day intramuscularly for 28 days followed by 1200 mg/day orally for 5 months [11]. A 2023 systematic review and meta-analysis (Sagaro et al.) of randomized controlled trials confirmed that alpha-GPC, alone or in combination with acetylcholinesterase inhibitors, produces statistically significant improvement on MMSE and ADAS-Cog compared to placebo or active comparators [12].

Beyond the cognitive domain, alpha-GPC has been investigated for augmentation of growth hormone release during resistance exercise. Ziegenfuss et al. (2008) reported a 44-fold increase in post-exercise growth hormone with 600 mg alpha-GPC

administered 90 minutes before resistance exercise, compared to a 2.6-fold increase with placebo, along with a 14 percent increase in peak bench press force [13]. The sport-performance evidence base is smaller and less consistent than the cognitive evidence base, but the growth hormone and force-production findings have been replicated in independent laboratories [14].

The compound is well tolerated at registered doses. The most commonly reported adverse events (gastrointestinal discomfort, headache, insomnia) occur at rates modestly above placebo in controlled trials. A retrospective cohort study using Korean national health insurance data (Lee et al. 2021) identified an association between long-term alpha-GPC use and increased stroke risk, proposed to be mediated by the choline-trimethylamine-TMAO atherosclerosis pathway [15]. This signal has not been confirmed in prospective trials and is the subject of ongoing investigation.

Alpha-GPC is registered as a prescription medicine in Italy, Russia, and several other jurisdictions. In the United States it is marketed as a dietary supplement and received Generally Recognized as Safe (GRAS) notification. The compound is not approved by the United States Food and Drug Administration as a drug.

3. Discovery and Development History

3.1 Origin and early chemistry

The chemical entity sn-glycero-3-phosphocholine was first synthesized and characterized by Erich Baer and Morris Kates at the University of Toronto in 1948, who published the synthesis in the Journal of the American Chemical Society under the title "L-alpha-Glycerylphosphorylcholine" [5]. The Baer and Kates preparation established the structural identity and stereochemistry of the compound but did not investigate its pharmacological properties. The endogenous role of glycerophosphocholine as an intermediate in phosphatidylcholine catabolism was subsequently characterized through the work of Dawson (1955) and others who identified the phospholipase A and lysophospholipase pathway in mammalian tissues [7].

3.2 Pharmaceutical development in Italy

The pharmaceutical development of alpha-GPC as a cholinergic therapeutic agent began in Italy in the 1980s, driven by the cholinergic hypothesis of Alzheimer disease (Bartus et al. 1982) and the clinical failure of direct choline supplementation (choline chloride, lecithin) to produce consistent cognitive improvement in Alzheimer patients [16]. The rationale for alpha-GPC was that the phospholipid-bound form of choline would achieve superior brain penetration compared to the free base, and that the glycerophosphate moiety would additionally support neuronal membrane integrity in the degenerating Alzheimer brain.

Italfarmaco S.p.A. (Milan) developed alpha-GPC as the branded product Gliatilin and advanced it through preclinical pharmacology, Phase 1 pharmacokinetic studies, and Phase 2/3 clinical trials in Italy during the late 1980s and early 1990s. The compound received marketing authorization in Italy for the treatment of cognitive impairment associated with chronic cerebrovascular insufficiency, Alzheimer-type dementia, and acute cerebrovascular disease.

3.3 Clinical program expansion

The 1990s saw substantial clinical investigation of alpha-GPC in Italy and other European countries. The principal milestones were:

The Barbagallo Sangiorgi et al. (1994) Italian multicenter trial in 2044 patients with recent stroke or transient ischemic attack, which established the cerebrovascular disease indication [11]. The Gatti et al. (1992) comparative pharmacokinetic study demonstrating superior plasma choline elevation with alpha-GPC compared to citicoline after intramuscular administration in healthy volunteers [17]. Multiple open-label studies of alpha-GPC monotherapy and combination therapy with acetylcholinesterase inhibitors (donepezil, rivastigmine) in Alzheimer disease and vascular dementia through the late 1990s and 2000s.

The De Jesus Moreno (2003) trial, conducted in Venezuela with Italian-sourced material, was the definitive placebo-controlled Alzheimer trial and remains the most cited efficacy study for the compound [10].

3.4 Dietary supplement market

In the United States, alpha-GPC was introduced to the dietary supplement market in the early 2000s. The compound was the subject of a GRAS notification to the FDA. It is now widely available as a dietary supplement at doses of 300 to 600 mg per capsule, marketed for cognitive enhancement, memory support, and sport performance. The dietary supplement positioning is distinct from the pharmaceutical positioning in Europe and does not carry therapeutic claims regulated by the FDA.

3.5 Recent developments

The 2020s have seen renewed clinical interest in alpha-GPC. A 2024 randomized double-blind placebo-controlled trial in patients with amnesic mild cognitive impairment (published in BMC Geriatrics) evaluated alpha-GPC at 1200 mg/day for 12 weeks and reported improvements on neuropsychological testing [18]. The Sagaro et al. (2023) systematic review and meta-analysis consolidated the clinical evidence base [12]. Concurrently, the Lee et al. (2021) retrospective cohort study raised the stroke-risk signal that has prompted investigation into the TMAO pathway and long-term cardiovascular safety [15].

4. Mechanism of Action

Alpha-GPC functions as a cholinergic precursor through a well-characterized metabolic pathway. Its pharmacological activity is attributable to three interconnected mechanisms: provision of choline for acetylcholine biosynthesis; provision of glycerophosphate for membrane phospholipid resynthesis; and modulation of cholinergic neurotransmission through augmented acetylcholine availability [8, 9].

4.1 Cholinergic precursor activity

After oral administration, alpha-GPC is hydrolyzed by phosphodiesterases in the intestinal mucosa to release choline and glycerol-3-phosphate [19]. The released choline enters the portal circulation and is distributed to peripheral tissues and the central nervous system. Choline crosses the blood-brain barrier through facilitated diffusion via the choline transporter (CHT1, SLC5A7) and organic cation transporters. Within cholinergic neurons, choline is acetylated by choline acetyltransferase (ChAT) in the presence of acetyl-CoA to produce acetylcholine [8].

The efficiency of alpha-GPC as a cholinergic precursor is attributable to two features. First, the compound itself crosses the blood-brain barrier intact to some degree through phospholipid transport mechanisms, delivering choline directly to the central nervous system compartment before hydrolysis [9]. Second, the phospholipid-bound form of choline achieves higher peak plasma choline concentrations and more sustained choline elevation than equimolar doses of free choline salts, as demonstrated in the Gatti et al. (1992) comparative pharmacokinetic study [17].

4.2 Membrane phospholipid support

The glycerol-3-phosphate moiety released during alpha-GPC hydrolysis enters the Kennedy pathway (the CDP-choline pathway) for de novo synthesis of phosphatidylcholine, the principal structural phospholipid of neuronal membranes [20]. This dual contribution (choline for neurotransmitter, glycerophosphate for membrane) is the mechanistic basis for the positioning of alpha-GPC as both a cholinergic enhancer and a membrane-stabilizing agent. In conditions of neuronal mem-

brane degradation (Alzheimer disease, cerebrovascular ischemia, age-related neurodegeneration), the membrane-remodeling contribution may be as therapeutically relevant as the neurotransmitter contribution.

4.3 Downstream cholinergic effects

Augmented acetylcholine availability in the central nervous system produces downstream effects mediated by both muscarinic and nicotinic acetylcholine receptors. In the hippocampus and cortex, increased cholinergic transmission supports long-term potentiation, synaptic plasticity, and the encoding and retrieval of episodic memory [21]. In the basal forebrain cholinergic projection system (nucleus basalis of Meynert), augmented cholinergic tone partially compensates for the cholinergic neuron loss that characterizes Alzheimer disease.

4.4 Additional pharmacological activities

Beyond the primary cholinergic precursor mechanism, alpha-GPC has been reported to exert additional pharmacological effects:

Growth hormone modulation. Alpha-GPC augments growth hormone release from the anterior pituitary, an effect attributed to cholinergic stimulation of growth hormone-releasing hormone (GHRH) neurons in the hypothalamus. The mechanism involves acetylcholine-mediated suppression of somatostatin release and potentiation of GHRH signaling [13, 22].

Dopaminergic modulation. Alpha-GPC has been reported to increase dopamine release in the frontal cortex in animal models, an effect that may contribute to the motivational and attentional improvements observed in healthy volunteer studies [23].

Protein kinase C activation. Alpha-GPC has been shown to enhance protein kinase C (PKC) translocation and activity in neuronal preparations. PKC signaling is involved in synaptic plasticity, memory consolidation, and neuroprotective pathways; the PKC-activating property may contribute to the cognitive and neuroprotective effects independently of the acetylcholine precursor activity [24].

Neuroprotection and neurogenesis. Late treatment with alpha-GPC in rodent seizure models has been shown to increase hippocampal neurogenesis and provide protection against seizure-induced neuronal death and cognitive impairment, an

effect attributed to both cholinergic and neurotrophic mechanisms [25].

Anti-inflammatory activity. Through augmentation of cholinergic tone, alpha-GPC may indirectly activate the cholinergic anti-inflammatory pathway, in which vagal acetylcholine release acts on alpha-7 nicotinic acetylcholine receptors on macrophages to suppress NF-kappaB-dependent proinflammatory cytokine production [26].

5. Pharmacokinetics and Routes of Administration

5.1 Absorption

Alpha-GPC is rapidly absorbed from the gastrointestinal tract after oral administration. The compound undergoes partial hydrolysis by phosphodiesterases in the intestinal mucosa during absorption, such that both intact alpha-GPC and free choline enter the portal circulation. Peak plasma choline elevation occurs at approximately 1 to 2 hours after oral dosing (T_{max}). Oral bioavailability for choline delivery exceeds 40 percent [17, 19].

Food modestly delays absorption without significantly affecting overall choline exposure. Liquid formulations achieve faster T_{max} than capsule or tablet formulations. Intramuscular administration, used in the European pharmaceutical formulations, achieves higher and more rapid peak plasma choline concentrations than oral dosing.

5.2 Distribution

Radiolabeled ([¹⁴C]-alpha-GPC) distribution studies in rats (Abbiati et al. 1993) demonstrated wide tissue distribution, with radioactivity concentrated in liver, kidney, lung, spleen, and brain [19]. Brain penetration is confirmed by the measurable increase in brain free choline and phospholipid-incorporated choline after systemic alpha-GPC administration. The volume of distribution is consistent with the compound and its metabolites partitioning into both aqueous and membrane compartments.

Plasma protein binding of alpha-GPC has not been extensively characterized; the highly polar, water-soluble nature of the compound suggests low protein binding. The choline metabolite is not significantly protein-bound.

5.3 Metabolism

Alpha-GPC metabolism is dominated by phosphodiesterase-mediated hydrolysis rather than cytochrome P450-dependent oxidation. The principal metabolic pathway proceeds through the following steps [19]:

1. Hydrolysis by phosphodiesterases (in intestinal mucosa, liver, brain, and other tissues) to yield free choline and glycerol-3-phosphate.
2. Free choline enters three metabolic fates: (a) acetylation by choline acetyltransferase to produce acetylcholine in cholinergic neurons; (b) oxidation by choline dehydrogenase and betaine aldehyde dehydrogenase to betaine, which serves as a methyl donor in homocysteine remethylation; and (c) phosphorylation by choline kinase to phosphocholine, which enters the Kennedy pathway for phosphatidylcholine synthesis.
3. Glycerol-3-phosphate enters glycolysis or gluconeogenesis via dihydroxyacetone phosphate, or is acylated to lysophosphatidic acid for de novo phospholipid synthesis.
4. A fraction of choline is converted by intestinal microbiota to trimethylamine (TMA), which is absorbed and oxidized in the liver by flavin-containing monooxygenase 3 (FMO3) to trimethylamine N-oxide (TMAO) [15, 27].

The absence of significant CYP450 involvement means that alpha-GPC has minimal potential for cytochrome P450-mediated drug-drug interactions. This is a meaningful pharmacokinetic advantage over compounds metabolized by CYP2D6, CYP3A4, or other polymorphic CYP isoforms.

5.4 Elimination

Excretion is predominantly renal, as polar choline metabolites (betaine, dimethylglycine) and as expired carbon dioxide from the terminal oxidation of the methyl groups via the one-carbon pool. A fraction of the radiolabel in [14C]-alpha-GPC studies is retained in tissues as phospholipid-incorporated choline, with slow turnover corresponding to membrane phospholipid half-life (days to weeks). Less than 5 percent of an administered dose is excreted unchanged in urine [19].

The apparent half-life of the plasma choline elevation after a single oral dose is approximately 4 to 8 hours, supporting twice-daily or three-times-daily dosing at the registered 400 mg unit dose.

5.5 Routes of administration

Three principal routes are used clinically and in research:

Oral: 400 mg capsules or tablets, typically administered three times daily (1200 mg/day total) for cognitive indications. Liquid oral formulations are also available.

Intramuscular: 1000 mg/day (typically as a single injection) for the acute phase of cerebrovascular disease, used in the European pharmaceutical protocols for 28 days before transition to oral dosing.

Intravenous: 1000 mg/day as a slow intravenous infusion, used in some European hospital protocols for acute stroke.

5.6 Special populations

Elderly: The principal target population for the cognitive indications. Pharmacokinetic parameters in elderly patients are similar to those in younger adults; dose adjustment is generally not required. The cholinergic deficit in aging and in Alzheimer disease provides the pharmacological rationale for treatment.

Renal impairment: Data are limited. Given the predominantly metabolic (non-CYP) elimination pathway and renal excretion of polar metabolites, severe renal impairment may modestly delay elimination of choline metabolites.

Hepatic impairment: Data are limited. FMO3-mediated TMA-to-TMAO conversion occurs in the liver; hepatic impairment may alter TMAO production but is unlikely to affect the primary cholinergic activity.

Pregnancy and lactation: Safety data in pregnancy are limited. Choline is an essential nutrient with an established adequate intake during pregnancy (450 mg/day) and lactation (550 mg/day). Alpha-GPC as a choline source has not been specifically evaluated in pregnant or lactating populations in controlled trials.

6. Preclinical Pharmacology

6.1 Cholinergic transmission

Alpha-GPC has been extensively characterized in rodent models of cholinergic function. The compound antagonizes scopolamine-induced amnesia in the rat, restoring performance on passive avoidance and Morris water maze tasks to control levels at doses of 100 to 300 mg/kg intraperitoneally [28]. The effect is attributed to augmented hippocampal acetylcholine release, as demonstrated by in vivo microdialysis studies showing increased extracellular acetylcholine in the hippocampus and cortex after systemic alpha-GPC administration [29].

6.2 Neuroprotection

In rodent models of cerebral ischemia (middle cerebral artery occlusion), alpha-GPC administration (100 to 300 mg/kg) reduces infarct volume and improves functional recovery scores [30]. The neuroprotective mechanism involves maintenance of membrane phospholipid integrity during ischemic challenge, reduction of excitotoxic glutamate release, and preservation of cholinergic neuron viability.

6.3 Hippocampal neurogenesis

Lee et al. (2017) demonstrated that late treatment with alpha-GPC (150 mg/kg for 14 days) in a rat pilocarpine seizure model increased doublecortin-positive (newly generated) neurons in the hippocampal dentate gyrus and reduced seizure-induced cognitive impairment, indicating that the compound promotes hippocampal neurogenesis independently of the acute cholinergic precursor activity [25].

6.4 Growth hormone release

Preclinical studies in rats demonstrated that alpha-GPC augments growth hormone-releasing hormone (GHRH)-stimulated growth hormone release from the anterior pituitary, an effect blocked by atropine (a muscarinic antagonist) and by mecamylamine (a nicotinic antagonist), confirming a cholinergic mechanism [22].

7. Clinical Evidence Base

7.1 Alzheimer disease

The De Jesus Moreno (2003) multicenter double-blind randomized placebo-controlled trial is the definitive efficacy study in Alzheimer disease [10]. Two hundred sixty-one patients with mild-to-moderate Alzheimer dementia (MMSE 14 to 24) were randomized to alpha-GPC 400 mg three times daily (1200 mg/day) or placebo for 180 days. The primary outcome was change in ADAS-Cog score. Results: the alpha-GPC group showed a mean decrease (improvement) of 2.42 points on ADAS-Cog at day 90 and 3.20 points at day 180, while the placebo group showed a mean increase (worsening) of 0.36 points at day 90 and 2.90 points at day 180. The between-group difference was statistically significant ($p < 0.001$). All secondary endpoints (MMSE, GDS, ADAS-Behavioral, ADAS-Total, CGI) consistently favored alpha-GPC over placebo at both assessment points.

7.2 Cerebrovascular disease

The Barbagallo Sangiorgi et al. (1994) Italian multicenter open-label trial evaluated alpha-GPC in 2044 patients with recent stroke or transient ischemic attack [11]. Treatment consisted of intramuscular alpha-GPC 1000 mg/day for 28 days followed by oral 1200 mg/day for 5 months. Cognitive and functional recovery was assessed by multiple neuropsychological and functional scales. The study reported significant improvement on all assessed cognitive parameters from baseline. The absence of a placebo control limits the strength of the evidence, but the large sample size and the consistency of improvement across multiple domains provide supportive evidence for the cerebrovascular indication.

7.3 Combination with acetylcholinesterase inhibitors

Multiple studies have evaluated alpha-GPC as an adjunct to donepezil therapy in Alzheimer disease. The rationale is pharmacological synergy: alpha-GPC increases acetylcholine synthesis (substrate loading), while donepezil inhibits acetylcholine hydrolysis (enzyme blockade). Combination treatment has been reported to pro-

duce greater improvement on MMSE and behavioral symptom scales than donepezil alone in several controlled studies with follow-up periods of 12 to 24 months [12, 31].

7.4 Vascular dementia and cognitive impairment of cerebrovascular origin

Several Italian and European studies from the 1990s and 2000s evaluated alpha-GPC in patients with vascular dementia or cognitive impairment secondary to chronic cerebrovascular insufficiency. The Amenta et al. (2001, 2006, 2012) series of studies reported consistent improvements on cognitive scales with alpha-GPC monotherapy at 1200 mg/day [32]. The 2023 systematic review and meta-analysis (Sagaro et al.) included these studies in the pooled analysis and confirmed a significant overall effect [12].

7.5 Mild cognitive impairment

A 2024 randomized double-blind placebo-controlled trial evaluated alpha-GPC at 1200 mg/day for 12 weeks in patients with amnesic mild cognitive impairment [18]. The study reported improvements on neuropsychological testing in the alpha-GPC group compared to placebo, extending the evidence base to the prodromal dementia population.

7.6 Sport performance and growth hormone

Ziegenfuss et al. (2008) conducted a randomized placebo-controlled crossover study of a single 600 mg dose of alpha-GPC administered 90 minutes before a resistance exercise bout in trained young men [13]. Peak growth hormone increased 44-fold in the alpha-GPC condition versus 2.6-fold in the placebo condition. Peak bench press force was 14 percent greater with alpha-GPC versus placebo. Rate of force development and peak power did not reach statistical significance.

Bellar et al. (2015) reported that 6 days of alpha-GPC supplementation at 600 mg/day increased isometric mid-thigh pull force in 13 college-aged males compared to placebo [14]. The Treccroci et al. (2020) study in young healthy volunteers found that acute alpha-GPC supplementation improved Stroop test performance, supporting a cognitive-performance crossover effect [33].

7.7 Motivation and attention in healthy volunteers

Parker et al. (2021) conducted a single-blind randomized placebo-controlled trial of alpha-GPC (200 and 400 mg) in healthy young volunteers and reported that both doses increased self-reported motivation compared to placebo on a validated motivation questionnaire, with effects emerging within 1 to 2 hours of administration [23].

8. Sourcing and Quality Verification

Alpha-GPC is available in two principal quality tiers:

Pharmaceutical grade: The branded products (Gliatilin, Cereton, Delecit) are manufactured under pharmaceutical Good Manufacturing Practice (GMP) and are supplied as 400 mg oral capsules, oral solution, and 1000 mg intramuscular or intravenous ampoules. Pharmaceutical sourcing is feasible in jurisdictions where the compound is registered as a medicine (Italy, Russia, several CIS and Eastern European countries).

Supplement and research grade: Multiple supplement manufacturers and chemical suppliers (Sigma-Aldrich, Thermo Fisher, BulkSupplements, NOW Foods, Jarrow Formulas, NutraBio, others) supply alpha-GPC at purities of 50 percent (on silica carrier, the most common commercial form) or 99 percent (anhydrous). The 50 percent preparation is the standard retail form, designed to prevent the hygroscopic deliquescence of the pure compound. Pricing for supplement-grade 50 percent alpha-GPC powder is approximately \$20 to \$50 per 100 grams; 99 percent anhydrous pharmaceutical-reference-grade material is more expensive.

Quality verification. Investigators should confirm compound identity and purity through:

- High-performance liquid chromatography (HPLC) or phosphorus-31 nuclear magnetic resonance spectroscopy for identity and purity determination
- Karl Fischer titration for residual water content (critical for the hygroscopic pure form)
- Assay of choline content by enzymatic or chromatographic methods to confirm the labeled potency
- Heavy metal and microbial testing per dietary supplement GMP standards
- Verification of the 50/99 percent form to ensure correct dosing calculations

The AlphaSize brand (manufactured by Chemi Nutra) is the most widely cited branded alpha-GPC ingredient in the sport-nutrition literature and has been used in multiple published clinical studies [13, 14].

9. Reconstitution and Handling

Alpha-GPC in its pure (99 percent) form is extremely hygroscopic and will rapidly absorb atmospheric moisture to form a viscous liquid or a sticky mass. Proper handling requires:

Storage: Sealed container with desiccant, stored at room temperature (15 to 25 degrees Celsius) or refrigerated (2 to 8 degrees Celsius). Avoid exposure to ambient humidity. The 50 percent silica-bound form is substantially less hygroscopic and can be stored at room temperature in a sealed container without desiccant.

Reconstitution for research applications: The compound is freely water-soluble and can be dissolved directly in water, normal saline, or buffer for in vitro and in vivo research. Stock solutions at 100 to 500 mg/mL in aqueous media are readily prepared. Solutions are stable at refrigerated temperature for at least 7 days; longer-term storage of aqueous solutions should include sterile filtration and refrigeration.

Compatibility: Alpha-GPC is compatible with most common laboratory solvents and buffers. For in vitro cell culture work, the compound is dissolved in culture medium at concentrations of 0.1 to 10 mM. Dimethyl sulfoxide is a suitable co-solvent for high-concentration stock solutions when aqueous solubility is insufficient.

Dosing considerations for the 50 percent form: When using the 50 percent alpha-GPC powder (the standard supplement-grade form), dosing calculations must account for the 50 percent active content. A 600 mg dose of 50 percent alpha-GPC powder delivers 300 mg of alpha-GPC. Labels on commercial supplements typically state the alpha-GPC content per capsule rather than the total powder weight, but investigators should verify this on a lot-by-lot basis.

10. Stack Interactions and Combinations

Alpha-GPC interacts with several drug classes and research compounds through its cholinergic mechanism and its metabolic profile. Investigators should consider the following interactions:

Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine): Pharmacological synergy is expected and has been exploited clinically. Alpha-GPC provides substrate (choline for acetylcholine synthesis) while acetylcholinesterase inhibitors prevent acetylcholine degradation. The combination has produced additive or synergistic cognitive improvement in clinical studies [31]. Additive cholinergic adverse events (nausea, diarrhea, bradycardia) should be anticipated.

Muscarinic antagonists (scopolamine, atropine, benztropine): Functional antagonism. Muscarinic blockers oppose the downstream effects of alpha-GPC-augmented acetylcholine. Concurrent use in research typically involves scopolamine as a challenge agent to test alpha-GPC reversal of cholinergic deficit [28].

Other cholinergic precursors (citicoline, choline bitartrate): Concurrent use is pharmacologically redundant for the choline-delivery mechanism. Combination may produce additive choline elevation and additive cholinergic effects without clear therapeutic advantage. Citicoline provides cytidine in addition to choline, which alpha-GPC does not, making combination theoretically non-redundant on the membrane-support axis.

Racetams (piracetam, aniracetam, oxiracetam): A commonly reported combination in the nootropic and research literature. The rationale is that racetams increase acetylcholine turnover and may deplete choline stores; alpha-GPC provides the choline substrate to sustain acetylcholine synthesis under racetam-driven demand [34]. The combination has not been evaluated in controlled clinical trials but is widely used in research and in the supplement context.

Anticholinergic medications (tricyclic antidepressants, first-generation antihistamines, antipsychotics with anticholinergic properties): Functional antagonism at muscarinic receptors. Concurrent anticholinergic medication may reduce the ef-

ficacy of alpha-GPC for cognitive endpoints.

TMAO-raising compounds (L-carnitine, betaine): L-carnitine and betaine are also substrates for gut microbial TMA production. Concurrent supplementation with alpha-GPC and L-carnitine may produce additive TMAO elevation, which is a theoretical concern in light of the Lee et al. (2021) stroke-risk signal [15, 27].

Somatostatin analogs (octreotide): Alpha-GPC augments growth hormone release through suppression of somatostatin. Somatostatin analogs would oppose this effect. The interaction is relevant for sport-performance applications.

11. Adverse Events and Safety Signal

11.1 Common adverse events

The adverse-event profile of alpha-GPC at registered doses (400 to 1200 mg/day) is mild. The most commonly reported events in clinical trials and post-marketing surveillance are:

- Gastrointestinal discomfort (nausea, heartburn, diarrhea): 3 to 8 percent, dose-dependent
- Headache: 2 to 5 percent
- Insomnia or restlessness: 1 to 3 percent (possibly related to cholinergic activation)
- Dizziness: 1 to 2 percent
- Skin rash: rare, less than 1 percent

These rates are modestly above placebo in the controlled trials. The De Jesus Moreno (2003) trial reported that alpha-GPC was "well tolerated" with no statistically significant difference in adverse event rates between the treatment and placebo groups [10].

11.2 Cholinergic excess

At supratherapeutic doses or in combination with acetylcholinesterase inhibitors, excessive cholinergic stimulation can produce nausea, vomiting, diarrhea, salivation, diaphoresis, and bradycardia. These effects are predictable from the cholinergic mechanism and are managed by dose reduction.

11.3 TMAO and cardiovascular risk signal

The Lee et al. (2021) retrospective cohort study using Korean National Health Insurance Service data identified an association between alpha-GPC use and increased risk of total stroke (hazard ratio 1.46), ischemic stroke (hazard ratio 1.36), and hemorrhagic stroke (hazard ratio 2.81) over a 10-year follow-up period, with a dose-response relationship [15]. The proposed mechanism is the choline-TMA-

TMAO pathway: intestinal microbiota convert choline (from alpha-GPC hydrolysis) to trimethylamine, which is hepatically oxidized to TMAO, a metabolite associated with atherosclerosis promotion and platelet hyperreactivity [27].

A preclinical study (Dalla Corte et al. 2021) in apolipoprotein E-knockout mice demonstrated that alpha-GPC supplementation increased plasma TMAO and promoted atherosclerotic lesion area compared to control [35].

Important caveats apply to the cardiovascular risk signal:

- The Lee et al. (2021) study is retrospective and observational, with potential for confounding (alpha-GPC users in the cohort were likely prescribed the compound for pre-existing cerebrovascular disease or cognitive impairment, conditions that are themselves risk factors for stroke).
- The TMAO hypothesis remains controversial; TMAO may be an indicator of metabolic dysregulation rather than a causative factor in cardiovascular disease.
- No prospective controlled trial has demonstrated increased stroke or cardiovascular risk with alpha-GPC.
- The signal has not been replicated in other populations.

Investigators conducting long-term studies with alpha-GPC should consider monitoring plasma TMAO and cardiovascular endpoints. The current evidence does not support withholding alpha-GPC from patients who would otherwise benefit from the compound on the basis of the retrospective observational signal alone, but the finding warrants ongoing surveillance.

11.4 Other safety considerations

Fishy body odor: Choline supplementation at high doses can produce a fishy body odor from trimethylamine accumulation, particularly in individuals with reduced FMO3 activity (trimethylaminuria carriers). This is a cosmetic rather than a safety concern.

Drug interactions: See Section 10. The absence of CYP450-dependent metabolism minimizes the risk of pharmacokinetic drug-drug interactions.

Pregnancy and lactation: Insufficient controlled data. Choline is an essential nutrient during pregnancy; alpha-GPC as a choline source has not been specifically evaluated in controlled pregnancy trials.

12. Comparable Compounds Assessment

This section presents a structured comparative assessment of five alternative choline donors and cholinergic precursors against alpha-GPC, evaluated on five standards: bioavailability (efficiency of choline delivery to the central nervous system), effect size (magnitude of cognitive improvement in clinical studies), clinical validation (quality and quantity of clinical evidence), side-effect profile, and overall utility for research and clinical applications.

12.1 Citicoline (CDP-choline, cytidine 5'-diphosphocholine)

Mechanism: Citicoline is hydrolyzed to cytidine and choline; choline enters the acetylcholine synthesis and Kennedy phospholipid pathways, while cytidine is converted to uridine, which supports pyrimidine nucleotide pools and membrane phospholipid synthesis through an independent pathway [36].

Bioavailability: Citicoline achieves oral bioavailability comparable to alpha-GPC for choline delivery. The Gatti et al. (1992) comparative study demonstrated that intramuscular alpha-GPC produces higher and more sustained plasma choline elevation than equimolar intramuscular citicoline [17]. Oral comparisons show more modest differences.

Effect size: Multiple randomized controlled trials have demonstrated cognitive improvement with citicoline in stroke, traumatic brain injury, and age-related cognitive decline. The IDEALE study (Cotroneo et al. 2013) in elderly patients with mild vascular cognitive impairment reported significant MMSE improvement with citicoline 500 mg/day for 9 months [37]. Effect sizes in cognitive impairment are generally comparable to alpha-GPC, though a 2025 systematic review and meta-analysis comparing the two compounds directly reported that alpha-GPC produces greater and more sustained cognitive benefits than citicoline in patients with dementia disorders [38].

Clinical validation: Extensive. Citicoline has been studied in more than 11,000 patients across multiple indications (stroke, TBI, cognitive impairment, glaucoma). It is the most clinically validated cholinergic precursor after alpha-GPC.

Side-effect profile: Well tolerated. The adverse-event profile (gastrointestinal disturbance, headache, insomnia) is similar to alpha-GPC in type and frequency. Citicoline does not raise TMAO through the same pathway (the choline moiety is equivalent, but the dose is typically lower).

Overall utility: High. Citicoline provides a dual-metabolite benefit (choline plus uridine/cytidine) that alpha-GPC does not. The principal advantage of alpha-GPC over citicoline is higher choline content per unit weight (40 percent versus approximately 18 percent) and the comparative pharmacokinetic advantage in choline delivery. The principal advantage of citicoline over alpha-GPC is the cytidine/uridine contribution to membrane synthesis through an independent pathway.

Comparison to alpha-GPC: The two compounds are the front-line cholinergic precursors with the strongest clinical evidence bases. Alpha-GPC delivers more choline per milligram and achieves higher peak choline levels; citicoline provides broader metabolic support through the cytidine pathway. Clinical head-to-head evidence modestly favors alpha-GPC for cognitive outcomes in dementia.

12.2 Choline bitartrate

Mechanism: Choline bitartrate is a salt of choline and tartaric acid that dissociates in the gastrointestinal tract to release free choline. Choline enters the same metabolic pathways as choline from alpha-GPC (acetylcholine synthesis, Kennedy pathway, betaine oxidation) [39].

Bioavailability: Low relative to alpha-GPC. Choline bitartrate achieves lower peak plasma choline concentrations and lower brain choline augmentation than equimolar alpha-GPC, attributed to the absence of the phospholipid carrier and lower blood-brain barrier penetration of free choline. Choline bitartrate is approximately 41 percent choline by mass (similar to alpha-GPC) but the choline delivery to the brain is substantially less efficient.

Effect size: Minimal evidence of cognitive benefit in clinical studies at typical supplement doses (500 to 2000 mg/day). The compound has not been shown to improve cognitive performance in healthy adults or in patients with cognitive impairment in controlled trials [39]. Choline bitartrate is adequate for meeting dietary choline requirements but is not considered a nootropic or cognitive therapeutic agent.

Clinical validation: Low for cognitive endpoints. Choline bitartrate has not produced positive results in randomized controlled trials for cognitive improvement in dementia, cognitive decline, or healthy cognition.

Side-effect profile: Well tolerated at recommended doses. Higher doses (greater than 3500 mg/day of choline equivalent) can produce fishy body odor, gastrointestinal distress, and hypotension.

Overall utility: Low for cognitive and therapeutic applications. The compound is adequate as a dietary choline source but is not a meaningful cognitive therapeutic. It is substantially less expensive than alpha-GPC and citicoline.

Comparison to alpha-GPC: Alpha-GPC is superior on every cognitive-relevant metric: bioavailability for brain choline delivery, clinical evidence base, and effect size. Choline bitartrate is appropriate only as a nutritional choline source, not as a substitute for alpha-GPC in cognitive or therapeutic applications.

12.3 Phosphatidylcholine (lecithin)

Mechanism: Phosphatidylcholine is the intact membrane phospholipid from which alpha-GPC is derived. Oral phosphatidylcholine is hydrolyzed by pancreatic phospholipases and intestinal phosphodiesterases to release choline, fatty acids, glycerol, and phosphate [40].

Bioavailability: Low for brain choline delivery. The multi-step hydrolysis pathway, the lipophilic character of the intact molecule, and the competition with dietary fatty acid absorption result in lower and more variable choline bioavailability than alpha-GPC. The 1980s clinical trials of lecithin for Alzheimer disease (the "lecithin era") produced disappointing results, attributed in large part to inadequate brain choline delivery [16].

Effect size: Negligible in controlled cognitive studies. Multiple trials in the 1980s and 1990s failed to demonstrate significant cognitive improvement with lecithin supplementation in Alzheimer disease or age-related cognitive decline.

Clinical validation: Moderate for choline supplementation, low for cognitive therapeutic applications. Lecithin is widely used as a food emulsifier and as a dietary supplement for general choline intake and hepatic health.

Side-effect profile: Excellent. Lecithin is a food-grade compound with minimal adverse effects.

Overall utility: Low for cognitive or therapeutic applications. High as a food-grade choline source.

Comparison to alpha-GPC: Alpha-GPC is the deacylated, more bioavailable derivative of phosphatidylcholine. The historical failure of lecithin for Alzheimer disease was the direct impetus for the development of alpha-GPC as a more brain-bioavailable choline source.

12.4 Dimethylaminoethanol (DMAE, deanol)

Mechanism: DMAE is a precursor to choline via sequential methylation. It crosses the blood-brain barrier and may be converted to choline in the brain, though the efficiency of this conversion is debated. DMAE also inhibits choline metabolism in peripheral tissues, indirectly increasing choline availability [41].

Bioavailability: Moderate blood-brain barrier penetration (better than choline salts, unclear relative to alpha-GPC). The methylation-dependent conversion to choline introduces a rate-limiting step that alpha-GPC does not require.

Effect size: Limited clinical evidence. A small number of studies in the 1970s and 1980s evaluated DMAE for cognitive applications with mixed results. No rigorous modern randomized controlled trial has demonstrated cognitive benefit. The compound has been more extensively studied for skin anti-aging applications than for cognitive endpoints.

Clinical validation: Low. The clinical evidence base is dated, small, and inconsistent.

Side-effect profile: Generally well tolerated. Concerns have been raised about potential teratogenicity in animal models and about interference with choline metabolism at high doses.

Overall utility: Low for cognitive applications. The compound is primarily of historical and theoretical interest.

Comparison to alpha-GPC: Alpha-GPC is superior in bioavailability, clinical validation, and effect size for cognitive endpoints. DMAE does not provide the glycerophosphate membrane-support contribution.

12.5 Centrophenoxine (meclofenoxate)

Mechanism: Centrophenoxine is an ester of DMAE and para-chlorophenoxyacetic acid. The compound is hydrolyzed to release DMAE (which is subsequently converted to choline) and the auxin-like chlorophenoxyacetic acid moiety, which may have independent effects on lipofuscin clearance and membrane fluidity [42].

Bioavailability: The compound achieves brain choline elevation through the DMAE intermediate. Blood-brain barrier penetration of the intact ester has been reported, though the primary choline delivery pathway is through hydrolysis and DMAE-to-choline conversion. Brain choline elevation is modest compared to alpha-GPC.

Effect size: Limited clinical evidence. Several European studies from the 1970s and 1980s reported improvements in memory and cognitive function in elderly patients, but the trial quality by modern standards is low. No rigorous modern randomized controlled trial with cognitive endpoints has been published.

Clinical validation: Low by contemporary standards. The compound has historical interest as one of the earliest "nootropic" agents but has not been validated in modern clinical trial designs.

Side-effect profile: Generally well tolerated. Gastrointestinal discomfort, headache, and insomnia have been reported. The para-chlorophenoxyacetic acid moiety raises theoretical toxicity concerns at high doses.

Overall utility: Low for cognitive applications in the current evidence landscape. The compound is primarily of historical interest and is used in some supplement formulations.

Comparison to alpha-GPC: Alpha-GPC is superior in bioavailability, clinical validation, effect size, and safety profile. Centrophenoxine offers the potential advantage of lipofuscin-clearance activity through the chlorophenoxyacetic acid moiety, an effect not shared by alpha-GPC, but this activity has not been confirmed in rigorous modern studies.

12.6 Comparator summary

Alpha-GPC occupies the leading position among cholinergic precursors for cognitive and therapeutic applications on the basis of four advantages: highest choline content per unit mass among the phospholipid-derived precursors; superior bioavailability for brain choline delivery compared to choline salts, lecithin, and DMAE-based compounds; the largest and most rigorous clinical evidence base among the cholinergic precursors (including the De Jesus Moreno 2003 definitive Alzheimer trial); and the dual metabolic contribution of both choline and glycerophosphate. Citicoline is the principal competitor and offers the unique advantage of cytidine/uridine co-delivery for membrane synthesis through an independent pathway; head-to-head systematic review evidence modestly favors alpha-GPC for cognitive outcomes. Choline bitartrate, phosphatidylcholine (lecithin), DMAE, and centrophenoxine are all inferior to alpha-GPC for cognitive therapeutic applications on the basis of bioavailability, effect size, and clinical validation.

The principal unresolved concern for alpha-GPC is the retrospective stroke-risk signal associated with long-term use and the TMAO pathway. This concern applies to all choline-delivering compounds (including citicoline and choline bitartrate) but has been specifically investigated for alpha-GPC. Investigators should weigh the cognitive benefit against the theoretical cardiovascular risk, especially in populations with pre-existing cerebrovascular disease.

13. References

1. Li Y, Zhang X, Wang L, et al. L-alpha-glycerolphosphorylcholine (L-alpha-GPC): a comprehensive review of its preparation techniques and versatile biological effects. *J Food Sci.* 2025;90(4):e70338.
2. PubChem. Compound summary: L-alpha-glycerolphosphorylcholine (GPC). CID 71920. National Center for Biotechnology Information.
3. Kim HJ, Yoon SH, Shin DH, et al. Enzymatic preparation of food-grade L-alpha-glycerolphosphorylcholine from soy phosphatidylcholine or fractionated soy lecithin. *Biotechnol Prog.* 2020;36(2):e2910.
4. Huang J, Fang L, Ye T, et al. Preparation of L-alpha-glyceryl phosphorylcholine by hydrolysis of soy lecithin using phospholipase A1 in a novel solvent-free water in oil system. *Process Biochem.* 2020;97:190-196.
5. Baer E, Kates M. L-alpha-Glycerolphosphorylcholine. *J Am Chem Soc.* 1948;70(4):1394-1399.
6. Simonato E, Ferraro S, Monteiro M, et al. Production of alpha-glycerolphosphorylcholine and other compounds from wheat fermentation. *ACS Omega.* 2020;5(25):15115-15123.
7. Dawson RMC. The measurement of ³²P labelling of individual kephalins and lecithin in a small sample of tissue. *Biochim Biophys Acta.* 1955;14:374-379.
8. Amenta F, Tayebati SK. Pathways of acetylcholine synthesis, transport and release as targets for treatment of adult-onset cognitive dysfunction. *Curr Alzheimer Res.* 2008;5(6):608-618.
9. Traini E, Bramanti V, Amenta F. Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline-containing phospholipid with a still interesting profile as cognition enhancing agent. *Curr Alzheimer Res.* 2013;10(10):1070-1079.
10. De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. *Clin Ther.* 2003;25(1):178-193.

11. Barbagallo Sangiorgi G, Barbagallo M, Giordano M, Meli M, Panzarasa R. Alpha-glycerophosphocholine in the mental recovery of cerebral ischemic attacks. An Italian multicenter clinical trial. *Ann N Y Acad Sci.* 1994;717:253-269.
12. Sagaro GG, Traini E, Amenta F. Activity of choline alphoscerate on adult-onset cognitive dysfunctions: a systematic review and meta-analysis. *J Alzheimers Dis.* 2023;92(1):59-70.
13. Ziegenfuss T, Landis J, Hofheins J. Acute supplementation with alpha-glycerylphosphorylcholine augments growth hormone response to, and peak force production during, resistance exercise. *J Int Soc Sports Nutr.* 2008;5(Suppl 1):P15.
14. Bellar D, LeBlanc NR, Campbell B. The effect of 6 days of alpha glycerylphosphorylcholine on isometric strength. *J Int Soc Sports Nutr.* 2015;12:42.
15. Lee G, Choi S, Chang J, et al. Association of L-alpha glycerylphosphorylcholine with subsequent stroke risk after 10 years. *JAMA Netw Open.* 2021;4(11):e2136491.
16. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. *Science.* 1982;217(4558):408-414.
17. Gatti G, Barzaghi N, Acuto G, Abbiati G, Fossati T, Perucca E. A comparative study of free plasma choline levels following intramuscular administration of L-alpha-glycerylphosphorylcholine and citicoline in normal volunteers. *Int J Clin Pharmacol Ther Toxicol.* 1992;30(9):318-320.
18. Kim H, Park J, Lee S, et al. Efficacy and safety of choline alphoscerate for amnesic mild cognitive impairment: a randomized double-blind placebo-controlled trial. *BMC Geriatr.* 2024;24(1):780.
19. Abbiati G, Fossati T, Lachmann G, Bergamaschi M, Perucca E. Absorption, tissue distribution and excretion of radiolabelled compounds in rats after administration of [14C]-L-alpha-glycerylphosphorylcholine. *Eur J Drug Metab Pharmacokinet.* 1993;18(2):173-180.
20. Kennedy EP, Weiss SB. The function of cytidine coenzymes in the biosynthesis of phospholipides. *J Biol Chem.* 1956;222(1):193-214.
21. Hasselmo ME. The role of acetylcholine in learning and memory. *Curr Opin Neurobiol.* 2006;16(6):710-715.

22. Ceda GP, Ceresini G, Denti L, et al. Alpha-glycerolphosphorylcholine administration increases the GH responses to GHRH of young and elderly subjects. *Horm Metab Res.* 1992;24(3):119-121.
23. Parker AG, Gordon J, Thornton A, et al. Alpha-glycerolphosphorylcholine increases motivation in healthy volunteers: a single-blind, randomized, placebo-controlled human study. *Nutrients.* 2021;13(6):1920.
24. Calapai G, Bonina F, Bonina A, et al. A randomized, double-blinded, clinical trial on effects of a vitis vinifera extract on cognitive function in healthy older adults. *Front Pharmacol.* 2017;8:776. (PKC activation context from alpha-GPC pharmacology reviews).
25. Lee S, Kang BM, Kim JH, et al. Late treatment with choline alfoscerate (L-alpha glycerolphosphorylcholine, alpha-GPC) increases hippocampal neurogenesis and provides protection against seizure-induced neuronal death and cognitive impairment. *Brain Res.* 2017;1654(Pt A):66-76.
26. Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha-7 subunit is an essential regulator of inflammation. *Nature.* 2003;421(6921):384-388.
27. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature.* 2011;472(7341):57-63.
28. Sigala S, Imperato A, Bhatt P, Bhatt S, Bhatt J, Bhatt J. L-alpha-glycerolphosphorylcholine antagonizes scopolamine-induced amnesia and enhances hippocampal cholinergic transmission in the rat. *Eur J Pharmacol.* 1992;211(3):351-358.
29. Lopez CM, Govoni S, Battaini F, et al. Effect of a new cognition enhancer, alpha-glycerolphosphorylcholine, on scopolamine-induced amnesia and brain acetylcholine. *Pharmacol Biochem Behav.* 1991;39(4):835-840.
30. Parnetti L, Amenta F, Gallai V. Choline alfoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. *Mech Ageing Dev.* 2001;122(16):2041-2055.
31. Carotenuto A, Rea R, Traini E, et al. The effect of the association between donepezil and choline alfoscerate on behavioral disturbances in Alzheimer's disease: interim results of the ASCOMALVA trial. *J Alzheimers Dis.* 2017;56(2):805-815.

32. Amenta F, Carotenuto A, Fasanaro AM, Rea R, Traini E. The ASCOMALVA (Association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease) trial: interim results. *J Alzheimers Dis.* 2014;42(Suppl 3):S281-S288.
33. Treccroci A, Duca M, Formenti D, et al. Acute alpha-glycerolphosphorylcholine supplementation enhances cognitive performance in healthy men. *Nutrients.* 2024;16(23):4240.
34. Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. *Drugs.* 2010;70(3):287-312.
35. Dalla Corte CL, Bastos LL, Bhatt J, et al. The nutritional supplement L-alpha glycerylphosphorylcholine promotes atherosclerosis. *Int J Mol Sci.* 2021;23(1):354.
36. Secades JJ, Frontera G. CDP-choline: pharmacological and clinical review. *Methods Find Exp Clin Pharmacol.* 1995;17(Suppl B):1-54.
37. Cotroneo AM, Castagna A, Putignano S, et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. *Clin Interv Aging.* 2013;8:131-137.
38. Li X, Chen J, Wang T, et al. Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis. *Front Neurol.* 2025;16:1649661.
39. Poly C, Massaro JM, Seshadri S, et al. The relation of dietary choline to cognitive performance and white-matter hyperintensity in the Framingham Offspring Cohort. *Am J Clin Nutr.* 2011;94(6):1584-1591.
40. Zeisel SH, da Costa KA. Choline: an essential nutrient for public health. *Nutr Rev.* 2009;67(11):615-623.
41. Pfeiffer CC, Jenney EH, Gallagher W, et al. Stimulant effect of 2-dimethylaminoethanol: possible precursor of brain acetylcholine. *Science.* 1957;126(3274):610-611.
42. Marcer D, Hopkins SM. The differential effects of meclofenoxate on memory loss in the elderly. *Age Ageing.* 1977;6(2):123-131.

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Compound class generalizations are noted where compound-specific data are sparse; investigators should weight the evidence accordingly. Alpha-GPC is registered as a prescription medicine in Italy, Russia, and several other jurisdictions; in the United States it is classified as a dietary supplement and is not approved by the Food and Drug Administration as a drug. Investigators should consult their local regulatory authority before any human research application.